NasdaqGS - Delayed Quote • USD
Intra-Cellular Therapies, Inc. (ITCI)
At close: April 24 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 15 | 14 |
| Avg. Estimate | -0.32 | -0.21 | -0.65 | 1.09 |
| Low Estimate | -0.47 | -0.32 | -1 | -0.46 |
| High Estimate | -0.24 | -0.14 | -0.29 | 3.17 |
| Year Ago EPS | -0.46 | -0.45 | -1.46 | -0.65 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 15 | 15 |
| Avg. Estimate | 141.17M | 159.37M | 660.54M | 921.37M |
| Low Estimate | 136.91M | 155.58M | 652M | 792M |
| High Estimate | 144.8M | 165.4M | 675.6M | 1.05B |
| Year Ago Sales | 91.98M | 110.79M | 464.37M | 660.54M |
| Sales Growth (year/est) | 53.50% | 43.80% | 42.20% | 39.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.61 | -0.59 | -0.57 | -0.44 |
| EPS Actual | -0.46 | -0.45 | -0.25 | -0.3 |
| Difference | 0.15 | 0.14 | 0.32 | 0.14 |
| Surprise % | 24.60% | 23.70% | 56.10% | 31.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.32 | -0.21 | -0.65 | 1.09 |
| 7 Days Ago | -0.34 | -0.22 | -0.71 | 1.14 |
| 30 Days Ago | -0.33 | -0.21 | -0.67 | 1.28 |
| 60 Days Ago | -0.3 | -0.2 | -0.47 | 1.19 |
| 90 Days Ago | -0.32 | -0.23 | -0.54 | 1.56 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 5 | 5 | 3 |
| Up Last 30 Days | 5 | 7 | 8 | 7 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | 2 |
Growth Estimates
| CURRENCY IN USD | ITCI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 30.40% | -- | -- | 1.50% |
| Next Qtr. | 53.30% | -- | -- | 11.40% |
| Current Year | 55.50% | -- | -- | 5.20% |
| Next Year | 267.70% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 291.40% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/24/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 4/23/2024 |
| Maintains | Needham: Buy to Buy | 4/22/2024 |
| Maintains | Mizuho: Buy to Buy | 4/22/2024 |
| Maintains | Goldman Sachs: Neutral to Neutral | 4/17/2024 |
| Maintains | B of A Securities: Buy to Buy | 4/17/2024 |
Related Tickers
NBIX Neurocrine Biosciences, Inc.
138.97
-0.80%
AQST Aquestive Therapeutics, Inc.
3.9000
-8.88%
AVDL Avadel Pharmaceuticals plc
17.66
-2.38%
ALKS Alkermes plc
24.65
+1.61%
LNTH Lantheus Holdings, Inc.
65.21
+1.24%
ESPR Esperion Therapeutics, Inc.
2.1300
+1.91%
EVO Evotec SE
5.23
-32.95%
DCPH Deciphera Pharmaceuticals, Inc.
14.62
-0.34%
ALVO Alvotech
13.54
+1.04%
IRWD Ironwood Pharmaceuticals, Inc.
8.10
-2.53%